bioihbjkbjnl/mcl2 huggingface dataset:
Manual Diaphragm Release in Cleaning Laborer
Condition: Respiratory System Abnormalities
MeSH terms: Respiratory System Abnormalities
Study type: Interventional

Summary: 
      This study intended to examine the effect of manual diaphragm release on pulmonary function,
      chest wall mobility, and functional ability in female occupational cleaners with respiratory
      hazards.
    

Detailed description: 
      Cleaning chores have been linked to exposure to various chemical agents that have the
      potential to cause harmful effects on both the respiratory system and cardiovascular markers,
      many cleaning products and disinfectants contain ingredients that can act as airway
      irritants. One of the physical therapy procedures that is used to manage chest disorders is
      manual diaphragm release which aims to lengthen the diaphragm musculature whereas encouraging
      better and more proficient contraction.
    

Intervention name(s): Manual Diaphragm Release; control group
Intervention type(s): Other; Other
Intervention description(s): The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.; Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
Other intervention name(s): inspiratory resistance; Respiratory re-training
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Respiratory hazards; pulmonary function; chest wall mobility; functional ability; Manual Diaphragmatic Release
Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This study investigated the bioequivalence and drug-drug interaction of Metformin/Gliclazide
      fixed combination tablet compared to co-administration of individual tablets of Metformin and
      Gliclazide.
    


Intervention name(s): Metformin/Gliclazide Fixed Combination; Metformin; Gliclazide
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.; Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.; Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
Intervention MeSH terms: Metformin; Gliclazide
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: Metformin; Gliclazide; Bioequivalence; Drug-drug Interaction; Pharmacokinetics
Study Evaluating Prevenar in High-Risk Children
Condition: Pneumococcal Disease
MeSH terms: Pneumococcal Infections
Study type: Observational

Summary: 
      The purpose of this study is to estimate the local and systemic tolerability of Prevenar in
      children ages 2 to 5 years old in usual care settings.
    


Time perspective: Prospective
Keywords: Children; Vaccine; Prevenar
Fingertip Pulse Oximeter Clinical Test
Condition: SPO2
Study type: Observational

Summary: 
      The purpose of this study is to validate the SpO2 accuracy of pulse oximeter equipment in
      comparison to "gold-standard" measurements of blood SaO2 by a CO-oximeter
    


Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        healthy volunteers who consent to induced hypoxia and arterial blood sampling as part of
        the experimental procedure
      
Keywords: SPO2
Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss
Condition: Overweight; Obesity
MeSH terms: Overweight
Study type: Observational

Summary: 
      The primary objective of this trial is to evaluate the influence of consuming a tea catechin
      containing sports beverage on body fat mass during exercise-induced weight loss among
      overweight and obese men and women.
    

Detailed description: 
      The study will include two screening/baseline visits and six treatment visits over 12 weeks.
      During the treatment phase of the study, subjects will be instructed to consume one bottle of
      sports drink (500 ml) daily (total consumption of tea catechins in the active group = 540
      mg/d). Subjects will be asked to maintain a constant energy intake throughout the study
      period. Three-day diet records will be collected and analyzed at weeks 0, 6, and 12 to
      evaluate consistency of energy intake.

      All subjects will engage in an exercise program with a goal of maintaining 180 min/week of
      low- to moderate-intensity exercise (e.g., walking and other aerobic activities, 4-6 days per
      week). Three of the weekly exercise sessions will be supervised and 1-3 will be unsupervised.
      Subjects will be asked to wear a pedometer and record their daily physical activity (steps)
      each night in a physical activity diary. Diaries will be collected at each visit and used to
      evaluate exercise compliance. Dual energy X-ray absorptiometry (DEXA) and computed tomography
      (CT) scans will be performed at baseline (week 0) and at the end of the treatment (week 12).
      Additionally, body weight and abdominal circumference will be assessed at every clinic visit
      during the study. It is anticipated that subjects will expend 1000-1800 kcal per week above
      their baseline level in deliberate physical activity. Accordingly, the control group is
      expected to lose 1.5 to 2.8 kg of body fat during the 12-week treatment period
    

Intervention name(s): 500 mL/day of a beverage providing approximately 625 mg catechins; Control beverage matched for energy and caffeine content
Intervention type(s): Dietary Supplement; Other
Intervention description(s): Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins; 500 mL/day of a control beverage
Intervention MeSH terms: Caffeine
Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Subjects included generally healthy, normally sedentary men and women. Eligible
        participants were required to be 21 to 65 years of age, have a waist circumference ≥ 87 cm
        (women) or ≥ 90 cm (men), and total cholesterol ≥ 200 mg/dL at screening.
      
Keywords: green tea,; polyphenols,; weight loss,; body fat
"Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients"
Condition: Allergic Rhinitis
MeSH terms: Rhinitis; Rhinitis, Allergic
Study type: Interventional
Phase: Phase 3

Summary: 
      Background: Zingiber cassumunar Roxb., frequently known as Phlai in Thai, has been safely
      used as an antihistaminic and anti-inflammatory drug in Thai traditional medicine. Individual
      with allergic rhinitis may have positive response to Phlai.

      Objective: Investigators assessed the efficacy and safety of Phlai as a treatment for
      allergic rhinitis Design: The study was a 1-month, double-blind, randomized, parallel-group,
      intent-to-treat, multicenter, controlled trial in 267 patients at 7 hospitals in Thailand.
      Skin prick test-positive adults with allergic rhinitis ages 18 to 50 who were randomized into
      3 groups (Phlai 8mg/d, Phlai 4mg/d, placebo).

      Main outcome measures: Primary outcome was defined: improvement of total 5 symptoms scores
      (nasal obstruction, rhinorrhea, sneezing, itchy nose, itchy eyes) over a 4-week interval
      among Phlai 8mg/d, Phlai 4mg/d and placebo. Secondary endpoints were: assessments of
      rhinoconjunctivitis quality of life questionnaire, peak inspiratory nasal flow, nasal
      examination, adverse events, AST, ALT, Creatinine and BUN over a period of 4 weeks.
    


Intervention name(s): Phlai; Placebo oral capsule
Intervention type(s): Drug; Drug
Intervention description(s): Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks; Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Other intervention name(s): Zingiber cassumunar
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Participant in each arm will take medication provided by care providers who also do not know what kind of this medication
Masking: Double (Participant, Care Provider)
Primary purpose: Treatment
Keywords: Zingiber cassumunar; Phlai; compound D; herbal medicine; allergic rhinitis
Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)
Condition: Diabetic Retinopathy; Macular Edema
MeSH terms: Macular Edema; Diabetic Retinopathy; Edema
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is designed to report 3-year result of triple therapy of vitrectomy, intravitreal
      triamcinolone and macular laser photocoagulation for intractable diabetic macular edema.

      Previously author reported 1-year result(Am J Ophthalmol. 2007 Dec;144(6):878-885. Epub 2007
      Oct 15.).
    


Intervention name(s): Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation
Intervention type(s): Procedure
Intervention description(s): all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.
IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken.
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Diabetic macular edema; Combination therapy for DME; DME
How do Attitude About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time
Condition: Attitude
Study type: Observational

Summary: 
      The investigators hypothesize that common objections to P4P relate to potential loss of
      autonomy or concerns about adverse effects on patient care.
    

Detailed description: 
      We seek to establish baseline attitudes about Pay for Performance (P4P) in the OUHSC Dept of
      Anesthesiology and determine what differences exist between faculty, CRNAs and residents. We
      plan to resurvey annually to determine if attitudes change as the department implements a P4P
      program. We hope that by understanding the attitudes of anesthesia care providers, we can
      alleviate their concerns. We hope to account for their concerns as we develop and modify our
      P4P program. We believe that acceptance of the general idea of P4P is important if
      individuals are to maintain job satisfaction.
    

Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        anesthesia care providers
      
Keywords: P4P
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Condition: Parkinson Disease
MeSH terms: Parkinson Disease; Dyskinesias
Study type: Interventional
Phase: Phase 2

Summary: 
      Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing
      properties. The primary target is the dopamine D3 receptor, a target implicated in the
      generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term
      levodopa treatment in patients with Parkinson's disease. In experimental animals mesdopetam
      potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian
      effect of levodopa.

      The primary purpose of the trial is to investigate whether mesdopetam given as adjunctive
      treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The
      trial will also help to establish the most optimal dosing of the compound.
    

Detailed description: 
      METHODOLOGY:

      This is a multicentre study where 74 patients with Parkinson's disease exhibiting levodopa
      induced dyskinesia will be randomised to receive study drug or placebo. Thirty seven patients
      will be randomised to mesdopetam and 37 patients to placebo (1:1 randomisation).

      Patients will be screened for eligibility according to inclusion/exclusion criteria within
      four weeks of initiation of study treatment (Screening visit).

      An outpatient study with the patients taking the study drug for four weeks at home.
      Mesdopetam will be taken twice daily (b.i.d.) as adjunctive treatment to the patients'
      regular and stable antiparkinsonian medication.

      The first two weeks of treatment will allow for per patient titration of study medication to
      the highest tolerated predefined dose, after which patients will continue on this highest
      tolerated dose for an additional two weeks.

      Changes in disease state and dyskinesia will be measured using the Unified Parkinson's
      Disease Rating Scale (MDS-UPDRS) and Unified Dyskinesia Rating Scale (UDysRS); furthermore,
      patients will administer two 24-hour diaries on run-in and on the fourth week of dosing to
      assess daily movements.

      Pharmacokinetic (PK) samples will be collected for the determination of concentrations of
      mesdopetam and its metabolites IRL902 and IRL872 in plasma. They will be collected before and
      after IMP administration at two visits.

      A Follow-up Visit will be performed for all patients five to eight days after last
      administration of IMP.
    

Intervention name(s): Mesdopetam (IRL790)
Intervention type(s): Drug
Intervention description(s): Mesdopetam (IRL790) capsule
Other intervention name(s): IRL790
Intervention MeSH terms: Mesdopetam
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Double blind, placebo controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Levodopa induced dyskinesia
Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain
Condition: Opioid-Related Disorders; Chronic Pain
MeSH terms: Musculoskeletal Pain; Chronic Pain; Opioid-Related Disorders
Study type: Interventional
Phase: Phase 1

Summary: 
      Pain is very common in persons with a history of addiction, but few studies have examined the
      best treatment of pain in this population. This is a study to determine the pain relief
      provided by intravenous hydromorphone (Dilaudid) or buprenorphine given to persons maintained
      on stable doses of methadone or buprenorphine who have chronic musculoskeletal pain.
      Experimental sessions will require overnight stays on a residential research unit. In these
      sessions, persons will be exposed to standard experimental pain techniques at baseline and
      then rate the relief (if any) provided by the study medication when exposed to the same
      techniques. Persons will be asked to participate in 3 sessions, each separated by at least 7
      days.
    


Intervention name(s): Buprenorphine; Hydromorphone; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.; Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.; Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Other intervention name(s): Suboxone; Subutex; Dilaudid; Normal Saline
Intervention MeSH terms: Buprenorphine; Hydromorphone
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Quantitative Sensory Testing; Hydromorphone; Buprenorphine
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Condition: Breast Cancer
MeSH terms: Breast Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to
      fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and
      Her2 normal.
    

Detailed description: 
      This is a single arm, non-randomized, open-label phase 2 study designed to evaluate the
      tolerability and clinical activity of adding enzalutamide to fulvestrant treatment in women
      with advanced breast cancer that are ER and/or PR-positive and Her2 normal. In this study 500
      mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of
      care (SOC) and 160mg of Enzalutamide will be, in conjunction with Fulvestrant, PO daily.
    

Intervention name(s): Fulvestrant with Enzalutamide
Intervention type(s): Drug
Intervention description(s): 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
Other intervention name(s): FASLODEX; MDV3100
Intervention MeSH terms: Fulvestrant
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Advanced Breast Cancer; ER+/Her2 Advanced Breast Cancer
Patient-specific Alloplastic Chin Implant Versus Computer Guided Genioplasty: Soft Tissue Assessment After One Year Follow up
Condition: Chin Microgenia
Study type: Interventional

Summary: 
      Two groups with retruded chin skeletal deformity. one treated with patient specific
      alloplastic implant and the other was treated with computer guided advancement genioplasty.
      soft tissue assessment was executed after one year
    


Intervention name(s): Polyetheretherketone patient specific implant; Computer guided advancement genioplasty
Intervention type(s): Device; Device
Intervention description(s): a customized peek patient specific implant is place to augment the chin; advancement genioplasty using patient specific cutting and positioning surgical stents
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Primary purpose: Treatment
Keywords: Chin microgenia; Orthognathic
Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
MeSH terms: Pancreatic Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate the clinical effectiveness of Gemcitabine/S-1
      combination chemoradiotherapy with Gemcitabine /S-1 combination chemotherapy for unresectable
      locally advanced pancreatic cancer.
    

Detailed description: 
      When cancer develops outside of the pancreas from within the anatomical placement of the
      pancreas itself, it becomes difficult to excise in most cases. Generally, most pancreatic
      cancers are already unresectable at the time of diagnosis when we have recognized
      infiltration of over 1/2 the circumference of major arteries such as the celiac artery and
      super mesenteric artery in particular.

      In comparison with advanced pancreatic cancer with distant metastases, it is not easy to
      treat unresectable locally advanced pancreatic cancer, even when performing standard
      gemcitabine monotherapy. In the case of unresectable locally advanced pancreatic cancers
      without distant metastases, we are left with the choice of whether or not to perform
      radiation therapy. This decision remains unsolved worldwide, despite the continuing efforts
      of researchers to bring an end to the clinical doubt.

      We will report our results as well as the problems of combining treatments with
      chemoradiotherapy, using the novel anticancer agent gemcitabine as well as/or S-1, not 5FU,
      predominantly from our own clinical trials on this occasion.
    

Intervention name(s): Drug: gemcitabine, S-1; gemcitabine, S-1, radiotherapy
Intervention type(s): Drug; Drug
Intervention description(s): Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.; Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
Other intervention name(s): gemzer; TS-1; gemzer; TS-1
Intervention MeSH terms: Gemcitabine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Bupivacaine Versus Bupivacaine Plus Lidocaine in Infraclavicular Block
Condition: Pain, Acute; Postoperative Pain; Analgesia
MeSH terms: Acute Pain
Study type: Interventional
Phase: Phase 4

Summary: 
      In this study, the investigators will compare two different anesthetic solutions in the
      infraclavicular block in patients having forearm, wrist, and hand surgery. The solutions will
      be bupivacaine 0.5% versus bupivacaine 0.25% plus lidocaine 1%, both associated with
      epinephrine 5 mcg/ml and dexamethasone 4 mg.

      The main objective of this investigation is to demonstrate that using higher concentrations
      of bupivacaine alone results in a significant block duration increase compared with the
      mixture of bupivacaine and lidocaine.
    


Intervention name(s): Bupivacaine-Lidocaine; Bupivacaine
Intervention type(s): Drug; Drug
Intervention description(s): Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml; Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Intervention MeSH terms: Lidocaine; Bupivacaine
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized Controlled Trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Supportive Care
Keywords: Bupivacaine; Lidocaine; Nerve Block; Infraclavicular Block; Upper Extremity Surgery